New combo aims to stop leukemia return after transplant

NCT ID NCT05270200

Recruiting now Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study is testing whether a combination of two drugs—azacitidine (given as a shot) and chidamide (taken as a pill)—can safely prevent high-risk acute myeloid leukemia from coming back after a stem cell transplant. About 20 adults aged 18 to 60 will receive six cycles of azacitidine plus up to two years of daily chidamide. Researchers will track side effects, relapse rates, and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine and chidamide
What this could lead to: If it works, this combination could help prevent leukemia from coming back after a stem cell transplant, giving patients more time without relapse.
What could go wrong: This is an early-phase study with only 20 participants, so results may not apply broadly. The drugs can cause side effects like low blood counts and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Nanfang Hospital of Southern Medical University
RECRUITING

Guanzhou, Guandong, 510250, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.